I'm LongbridgeAI, I can summarize articles.Medtronic (MDT) closed the week up 2.43% at $88.48, outpacing the S&P 500, which gained 1.15%. The stock swung around across the five sessions: Monday opened at $86.33, dipped to $85.53 intraday, then closed at $87.97; Tuesday touched $88.50 before slipping to $87.09; Wednesday slid to the week’s low of $85.43 and ended at $85.51; Thursday rebounded on higher turnover, with volume reaching 105.7m shares; Friday pushed to a week-high $89.81 before settling at $88.48.
The Week
Medtronic (MDT) closed the week up 2.43% at $88.48, outpacing the S&P 500, which gained 1.15%. The stock swung around across the five sessions: Monday opened at $86.33, dipped to $85.53 intraday, then closed at $87.97; Tuesday touched $88.50 before slipping to $87.09; Wednesday slid to the week’s low of $85.43 and ended at $85.51; Thursday rebounded on higher turnover, with volume reaching 105.7m shares; Friday pushed to a week-high $89.81 before settling at $88.48. The week’s range was $85.43 to $89.81.
Key Events
News flow centred on Medtronic’s own pipeline and the MiniMed spin-off. On 6 October, Medtronic published its FY26 Impact Report, showing a 68% cut in Scope 1 and 2 emissions intensity versus the FY20 baseline. On 7 October, it released 24-month TITAN 2 data showing sustained nocturia reduction with the Altaviva device, and separately won FDA clearance for ApexCut EM navigated sinus surgery blades. The same evening, it announced the final exchange ratio of 4.5939 for the split-off of MiniMed Group, Inc. SC TO-I/A and 425 filings during the week extended documentation around the deal. Later in the week, Leerink flagged that MedTech growth concerns could overshadow third-quarter results, while dividend-focused commentary included Medtronic among healthcare dividend names.
Analyst Ratings
Medtronic has 29 covering analysts: 16 rate it buy, 3 rate it overweight, and 10 rate it hold, with no sell or underweight ratings. The consensus rating is buy, and the consensus target of $104.44 sits about 18.04% above the latest close. Individual targets range from $85.00 to $121.00, a wide spread that suggests views differ on how far the re-rating can run. Within the medical-device industry, Medtronic ranks 6th out of 142 companies in terms of analyst ratings.
The Week Ahead
The coming week brings US inflation checks: NFIB small-business optimism and existing-home sales on 13 October, followed by CPI and core CPI on 14 October. A stronger-than-expected inflation print could shift rate expectations and, in turn, the relative appeal of high-dividend healthcare names. On the company front, execution of the MiniMed split-off remains a focus as the exchange ratio details settle.
In Short
Medtronic beat the broader market while the MiniMed separation and FDA clearance framed the week’s story. The consensus target sits well above the spot price, but the wide target range signals disagreement among analysts. On the latest session, large-lot money turned net seller while small and medium orders were net buyers, setting up a tension between positioning and the bullish-leaning ratings. The next tests are the CPI data and how the spin-off affects the company’s structure and dividend trajectory.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.